Research progress on Astragalus active ingredient in treatment of hepatic fibrosis based on cell signaling pathway

Author: Shu-Di LI ¹ ; Xiang-Xiang LI ¹ ; Xing YANG ¹ ; Zhen WANG ² ; Jiang-Kai LIU ² ; Fei DUAN ² ; Su-Ling LI ²
Author Information

1. The First Clinical Medical College of Henan, University of Chinese Medicine, The First Affiliated Hospital, Henan University of Chinese Medicine Henan, University of Chinese Medicine
2. Dept of Gastroenterology, The First Affiliated Hospital of Henan, University of Chinese Medicine, Henan University of Chinese Medicine
Publication Type:Journal Article
Keywords: Astragalus active ingredient; cell signaling pathway; hepatic fibrosis; mechanismof action; pathogenesis; pathway interaction
From: Chinese Pharmacological Bulletin 2023;39(1):18-23
CountryChina
Language:Chinese
Abstract: Hepatic fibrosis is present in most chronic liver disease processes, and there are no ideal anti-fibrotic drugs available. Astragalus has a long history of medicinal use, and its anti-fibrotic effects have been confirmed by modern studies. In this study we have searched the literature to identify the signaling pathways and mechanisms of action of Astragalus and its active ingredients on hepatic fibrosis in recent years, so as to provide the basis and ideas for the development of anti-fibrotic drugs and mechanisms of Astragalus. It is showed that the active ingredients of Astragalus act through regulating p38MAPK, TGF-pl/Smads,NF-